back to US directory
us clinical guidance

Acne vulgaris assessment and management

AAD-based acne severity assessment, combination topical treatment, antibiotic stewardship, isotretinoin referral and scar prevention for US practice.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Adults, adolescents and children older than nine years with acne vulgaris, the population addressed by the 2024 AAD guideline. Acne fulminans, a suspected medication or endocrine cause, pregnancy-specific prescribing, hidradenitis suppurativa and monomorphic infectious eruptions need a separate assessment.
sources for this section:AAD acne guideline 2024

The Bottom Line

  • Grade inflammatory and comedonal disease, distribution, nodules, existing or impending scars, post-inflammatory pigment change and psychosocial burden; treatment intensity should reflect risk of permanent harm as well as lesion count.
  • Use topical therapies with complementary mechanisms. The AAD strongly recommends benzoyl peroxide, topical retinoids, topical antibiotics and appropriate combinations, while conditionally supporting agents such as salicylic acid and azelaic acid.
  • Limit systemic antibiotic exposure, combine an oral antibiotic with benzoyl peroxide and other topical therapy, and maintain a non-antibiotic topical regimen after the systemic course whenever suitable.
  • Consider combined oral contraceptives or spironolactone for appropriate patients after contraindication and pregnancy-risk review; these are treatment choices, not substitutes for evaluating a new endocrine syndrome.
  • Refer or initiate the source-defined isotretinoin pathway for severe acne or acne that has failed standard oral or topical therapy, especially when nodules, scarring or major psychosocial burden are present.
sources for this section:AAD acne guideline 2024

Practical clinical workflow

1
Confirm polymorphic acne with comedones and inflammatory lesions; ask about onset, menstrual or androgenic features, medicines and supplements, skin and hair products, prior courses, pregnancy potential and mental-health impact.
2
Agree realistic goals and select a combination topical regimen matched to lesion type and tolerability; explain gradual introduction, irritation management, noncomedogenic skin care and daily photoprotection.
3
For moderate inflammatory disease needing an oral antibiotic, document the indication, combine with benzoyl peroxide and a topical retinoid where tolerated, and set a time-limited review rather than open-ended refills.
4
Reassess adherence, irritation, new scarring, pigment change and response before changing therapy; escalate early when permanent scarring is developing instead of repeating ineffective courses.
5
For isotretinoin or hormonal treatment, use current FDA labeling and pregnancy-prevention requirements, medication-specific laboratory or adverse-effect monitoring and shared decision-making.
sources for this section:AAD acne guideline 2024

Safety boundaries and escalation

  • Rapidly ulcerating or crusted nodules with fever, arthralgia or systemic illness may represent acne fulminans and needs urgent dermatology assessment.
  • New severe depression, suicidality, bullying, school avoidance or marked distress requires prompt mental-health assessment while skin treatment continues; do not dismiss morbidity because acne is common.
  • Avoid topical or systemic retinoid exposure in pregnancy and verify current product labeling; evaluate thrombotic and other contraindications before estrogen-containing contraception and potassium or renal risks before spironolactone.
  • Do not use topical antibiotic monotherapy or serial prolonged oral-antibiotic courses, because resistance and avoidable adverse effects undermine both the individual plan and antimicrobial stewardship.
sources for this section:AAD acne guideline 2024

Localization

The 2024 AAD recommendations and current FDA product labeling govern this summary. US isotretinoin risk-management requirements, state minor-consent rules and insurance step therapy affect implementation.
sources for this section:AAD acne guideline 2024

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. American Academy of DermatologyGuidelines of care for the management of acne vulgaris2024 update to the 2016 AAD guideline 路 published 2024-01-30 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.